Yuhan Corporation Unveils Clinical Trial Design for Oral HER2-Targeted Cancer Drug YH42946; Phase 2 to Begin Early Next Year
Yuhan Corporation Unveils Clinical Trial Design for Oral HER2-Targeted Cancer Drug YH42946; Phase 2 to Begin Early Next Year finance.biggo.com